EXAS: Exact Sciences

Wowwwwww.

The American Cancer Society finally came out with the new colorectal cancer screening guidelines, and stool-DNA has been approved!

This is huge for EXAS.
 
2 million shares traded so far just 3 hours into the day.... Conference Call scheduled after the close regarding the recent ACS Guideline inclusion and current 510k negotiations with the FDA.

EXAS: $3.42 $+1.33

( High of $4.25 off the opening )
 
The Company announced today that they have hired healthcare investment banker LEERINK SWANN to explore "strategic" options . . .

In other words, this company and its 37 patents on stool-DNA colorectal cancer screening is now in PLAY.

Hello Roche?
Abbott Labs?
Genetech?

:D
 
You must log in or register to reply here.
Back
Top